| Chemotherapy-induced cognitive impairment (CICI): An overview of etiology and pathogenesis NM Mounier, AES Abdel-Maged, SA Wahdan, AM Gad, SS Azab Life sciences 258, 118071, 2020 | 108 | 2020 |
| Comparative study of anti-VEGF Ranibizumab and Interleukin-6 receptor antagonist Tocilizumab in Adjuvant-induced Arthritis AES Abdel-Maged, AM Gad, AK Abdel-Aziz, MM Aboulwafa, SS Azab Toxicology and Applied Pharmacology 356, 65-75, 2018 | 30 | 2018 |
| Abrogating doxorubicin-induced chemobrain by immunomodulators IFN-beta 1a or infliximab: Insights to neuroimmune mechanistic hallmarks SA Wahdan, MO El-Derany, AE Abdel-Maged, SS Azab Neurochemistry international 138, 104777, 2020 | 22 | 2020 |
| Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling AE Abdel-Maged, AM Gad, SA Wahdan, SS Azab Toxicology and Applied Pharmacology 380, 114702, 2019 | 19 | 2019 |
| Repurposing of secukinumab as neuroprotective in cuprizone-induced multiple sclerosis experimental model via inhibition of oxidative, inflammatory, and neurodegenerative signaling AES Abdel-Maged, AM Gad, LA Rashed, SS Azab, EA Mohamed, ... Molecular neurobiology 57, 3291-3306, 2020 | 15 | 2020 |
| Biosimilars production in Africa opportunities & challenges AE Abdel-Maged, MF Mikhaeil, AI Elkordy, AM Gad, MM Elshazly Regulatory Toxicology and Pharmacology, 105626, 2024 | | 2024 |
| Abrogating doxorubicin-induced chemobrain by immunomodulators IFN-beta 1a or infliximab: Insights to neuroimmune mechanistic hallmarks (vol 138, 104777, 2020) SA Wahdan, MO El-Derany, AE Abdel-Maged, SS Azab NEUROCHEMISTRY INTERNATIONAL 166, 2023 | | 2023 |
| Corrigendum to" Abrogating doxorubicin-induced chemobrain by immunomodulators IFN-beta 1a or infliximab: Insights to neuroimmune mechanistic hallmarks"[Neurochem. Int. 138 … SA Wahdan, MO El-Derany, AE Abdel-Maged, SS Azab Neurochemistry International, 105525-105525, 2023 | | 2023 |
